40th anniversary Chevy Corvette raffled at 2013 Barrett-Jackson Collector Car Auction
Ruby red coupe raises funds for cancer investigations at non-profit TGen
SCOTTSDALE, Ariz. — Imagine buying a classic Chevy Corvette for just $50.
That’s the price of 1 ticket for a 1993 Chevrolet Corvette 40th Anniversary coupe being raffled at the 42nd annual Barrett-Jackson Collector Car Auction in Scottsdale to benefit cancer research at the Translational Genomics Research Institute (TGen).
Proceeds go to the Barrett-Jackson Cancer Research Fund at TGen, in Memory of Russ and Brian Jackson. The fund, established in 2010, is a salute to auction Chairman and CEO Craig Jackson’s father, Russ, and brother, Brian, whose lives were cut short by colon cancer.
“The Barrett-Jackson/TGen fund supports colon and prostate cancer research with the hope that new laboratory discoveries will pave the way for better treatments and improved quality of life for cancer patients,” Craig Jackson said. “I am very honored by the work TGen scientists are pursuing in memory of my dad and brother.”
The ruby red 1993 Corvette is one of the 40th anniversary models of this legendary sports car. The first Corvette was built in 1953.
If the description of this car seems familiar, it is the same one that has been auctioned, and then donated back to Barrett-Jackson, raising more than $300,000 in past two years for TGen’s non-profit research.
This year, the Corvette will be raffled. Tickets are $50 each, or 3 for $100. Raffle tickets will be sold by cash, check or charge Jan. 13-19 during the Barrett-Jackson Collector Car Auction at the TGen booth (N.E. corner of the SPX Showcase Pavilion), or online through Jan. 18 at www.bjcancerfund.org. The Corvette will be on display at the TGen booth. The TGen raffle winner will be notified Jan. 20.
The Barrett-Jackson Scottsdale Auction is Jan. 13-20 at Westworld of Scottsdale, northeast of Loop 101 and Frank Lloyd Wright Boulevard.
Although the raffle is being held at the auction, this promotion is being conducted by the TGen Foundation. Neither Barrett-Jackson Auction Co. LLC nor any of its affiliates have responsibility for conducting this promotion.
“Craig Jackson and his team at Barrett Jackson have become a tremendous force for TGen, not only in raising funds for cancer research, but in providing enhanced awareness of these diseases and the possibilities available through personalized medicine; treating each patient based on their unique genetic profile,” said Michael Bassoff, President of the non-profit TGen Foundation.
More than 140,000 Americans, men and women, were diagnosed last year with colon cancer, which in 2012 killed nearly 52,000 patients, the third-leading cause of cancer death in the U.S.
An additional 241,000 American men were diagnosed last year with prostate cancer, which in 2012 killed nearly 28,000 patients, the second-leading cause of cancer death among men in the U.S.
In addition to its annual Scottsdale event, Barrett-Jackson also conducts collector car auctions each year in: Palm Beach, Fla., and Las Vegas, Nev.
The 2012 Barrett-Jackson Scottsdale auction helped raise nearly $5.9 million for local and national charities.
About The Barrett-Jackson Auction Company
Established in 1971 and headquartered in Scottsdale, Ariz., Barrett-Jackson specializes in providing products and services to classic and collector car owners, astute collectors and automotive enthusiasts around the world. The company produces the “World’s Greatest Collector Car Auctions™” in Scottsdale, Palm Beach, Fla., and Las Vegas, Nev. For more information about Barrett-Jackson, visit www.barrett-jackson.com or call (480) 421-6694.
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.
This news content was configured by WebWire editorial staff. Linking is permitted.